IRCT20200623047902N20尚未招募未知
Bioequivalence study of Everolimus-Aqvida 10mg manufactured by Rooyan darou versus Afinitor 10 mg in healthy volunteers in the fasted condition
Rooyan darou company0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-65 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcohol and drug addiction
- •History of allergy to Everolimus
研究者
相似试验
招募中
不适用
Bioequivalence study of Everolimus 0.75mg tabletIRCT20200623047902N12Alborz Zagros company24
尚未招募
不适用
In-vivo Bioequivalence Test of NEORAPA® tablet with brand drugs (AFINITOR® 10mg Novartis).In this study, the disease is not examined. Subject bioequivalence test and reference tablets Everolimus studied..IRCT20200105046010N24ABIDI Pharmaceutical Company24
招募中
不适用
In-vivo Bioequivalence Test of Everolimus tablet with brand drugs (AFINITOR® 10mg Novartis).IRCT20200105046010N44SOBHAN ONCOLOGY Pharmaceutical CO.24
招募中
不适用
In-vivo Bioequivalence Test of Everolimus tablet (ROLIMA® 0.75 mg) with brand drugs (CERTICAN® 0.75 mg, Novartis,Switzerlan).IRCT20200105046010N58anoalvand Pharmaceutical Co.24
招募中
4 期
Bioequivalence Study of 5 mg Nebivolol Tablets in Healthy Thai Volunteers under Fasting ConditionsRecently,Company has manufactured a new formulation of nebivolol tablets 5 mg for which this study has been planned to evaluate the pharmacokinetics of the new formulation.TCTR20161115001Research and Development48